Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Prime Medicine, Inc. before investing.

In this article, we go over a few key elements for understanding Prime Medicine, Inc.’s stock price such as:

• Prime Medicine, Inc.’s current stock price and volume
• Why Prime Medicine, Inc.’s stock price changed recently
• Upgrades and downgrades for PRME from analysts
• PRME’s stock price momentum as measured by its relative strength

About Prime Medicine, Inc. (PRME)

Before we jump into Prime Medicine, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Prime Medicine, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Prime Medicine, Inc..

Prime Medicine, Inc.’s Stock Price as of Market Close

As of December 05, 2025, 3:59 PM, CST, Prime Medicine, Inc.’s stock price was $3.740.

Prime Medicine, Inc. is down 2.86% from its previous closing price of $3.850.

During the last market session, Prime Medicine, Inc.’s stock traded between $3.682 and $3.940. Currently, there are approximately 160.50 million shares outstanding for Prime Medicine, Inc..

Prime Medicine, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Prime Medicine, Inc. Stock Price History

Prime Medicine, Inc.’s (PRME) price is currently down 2.09% so far this month.

During the month of December, Prime Medicine, Inc.’s stock price has reached a high of $4.080 and a low of $3.260.

Over the last year, Prime Medicine, Inc. has hit prices as high as $6.940 and as low as $1.110. Year to date, Prime Medicine, Inc.’s stock is up 28.08%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Prime Medicine, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 05, 2025, there were 0 analysts who downgraded Prime Medicine, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Prime Medicine, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Prime Medicine, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Prime Medicine, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Prime Medicine, Inc. (PRME) by visiting AAII Stock Evaluator.

Relative Price Strength of Prime Medicine, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 05, 2025, Prime Medicine, Inc. has a weighted four-quarter relative price strength of 9.16%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Prime Medicine, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Prime Medicine, Inc. Stock Price: Bottom Line

As of December 5, 2025, Prime Medicine, Inc.’s stock price is $3.740, which is down 2.86% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Prime Medicine, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.